Climb Bio FY2026 Earnings Forecast Boosted by HC Wainwright

Climb Bio, Inc. (NASDAQ:CLYM) – Research analysts at HC Wainwright boosted their FY2026 earnings per share estimates for shares of Climb Bio in a report released on Monday, November 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.74) per share for the year, up from their previous forecast of ($0.76). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Climb Bio’s Q4 2026 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.25) EPS, Q4 2027 earnings at ($0.26) EPS and FY2027 earnings at ($0.97) EPS.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.02.

CLYM has been the subject of a number of other reports. BTIG Research reaffirmed a “buy” rating and issued a $32.00 target price on shares of Climb Bio in a research note on Tuesday, October 27th. Wall Street Zen raised shares of Climb Bio from a “sell” rating to a “hold” rating in a research report on Saturday. Robert W. Baird boosted their price target on shares of Climb Bio from $21.00 to $25.00 and gave the company an “outperform” rating in a research report on Thursday, September 3rd. Guggenheim reissued a “buy” rating on shares of Climb Bio in a report on Monday, October 26th. Finally, Piper Sandler reissued an “overweight” rating on shares of Climb Bio in a report on Tuesday, October 27th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $28.14.

Climb Bio Stock Performance

NASDAQ CLYM opened at $11.74 on Wednesday. The stock’s fifty day moving average is $11.80 and its two-hundred day moving average is $10.53. The firm has a market capitalization of $689.61 million, a P/E ratio of -14.32 and a beta of 0.01. Climb Bio has a fifty-two week low of $1.63 and a fifty-two week high of $18.33.

Insider Activity at Climb Bio

In other news, Director Stephen Thomas sold 100,000 shares of Climb Bio stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $13.67, for a total transaction of $1,367,000.00. Following the sale, the director owned 467,969 shares of the company’s stock, valued at approximately $6,397,136.23. The trade was a 17.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. State of Wyoming purchased a new stake in Climb Bio in the third quarter valued at $31,000. Legal & General Group Plc acquired a new position in shares of Climb Bio in the 2nd quarter valued at $45,000. Spark Investment Management LLC acquired a new position in shares of Climb Bio in the 2nd quarter valued at $177,000. Profund Advisors LLC acquired a new position in shares of Climb Bio in the 3rd quarter valued at $190,000. Finally, Bank of America Corp DE purchased a new position in shares of Climb Bio during the 2nd quarter worth $335,000. 69.76% of the stock is currently owned by hedge funds and other institutional investors.

About Climb Bio

Climb Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases, with a focus on conditions involving B cells and antibody production. Its lead candidate, budoprutug, is an antibody designed to engage CD19 and FcγRIIb to inhibit B-cell activity. The company is evaluating the candidate in clinical studies for immune-mediated diseases, including immune thrombocytopenia and membranous nephropathy. Climb Bio is also developing CLYM-116, an antibody targeting APRIL, a protein involved in B-cell and antibody activity.